10% Owner Sells Over $400K in Clene Inc. Shares Amidst Ongoing Insider Distribution
CLNN has more than doubled off its 52-week low of $2.28.
Summary
A 10% owner of Clene Inc. disposed of over $400,000 worth of common stock, continuing a trend of insider sales for the company which recently disclosed going concern doubts.
Key Events · Ownership and Investor Activity · CLNN
-
Substantial Insider Sale
A 10% owner, Ugwumba Chidozie, sold 65,663 shares of Clene Inc. common stock in two open market transactions on April 20-21, 2026, for a total value of $403,084.
-
Ongoing Insider Distribution
This sale contributes to a pattern of net insider selling, with over $1.2 million in sales by insiders over the past 90 days, including recent Form 144 and Form 4 filings from other insiders.
-
Financial Uncertainty Context
The insider selling occurs as Clene Inc. faces a 'going concern' warning, as disclosed in its most recent 10-K filing on March 17, 2026, indicating significant financial challenges.
Analysis · CLNN · Life Sciences
This Form 4 filing reports a significant open market sale of over $400,000 by a 10% owner of Clene Inc. This transaction continues a pattern of insider distribution, with over $1.2 million in net sales by insiders in the last 90 days. The sale occurs shortly after the company filed proxy statements seeking to increase shares for equity compensation and follows a Form 144 filing for an additional $670K in sales by a former board member. This ongoing insider selling, particularly from a major shareholder, adds to concerns given the company's recent disclosure of substantial doubt about its ability to continue as a going concern in its latest 10-K.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 29.2% of the 1541 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLNN was trading at $6.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.4M. The 52-week trading range was $2.28 to $13.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.